SREBF2 and cancer: Gain of function p53R175H mutation binds and activates SREBP-2, increasing its transcriptional activity of mevalonate enzymes, including HMGCR, acting as a constant “on switch” [23, 24], which drives cancer cell proliferation and inhibits apoptosis [6].